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Abstract
Objective—The CAPRISA 004 trial showed that coitally-dosed tenofovir 1% gel reduced HIV 
acquisition by 39% overall and 54% when used consistently. The objective of this analysis was to 
ascertain its pharmacokinetic-pharmacodynamic relationship to protection against HIV 
acquisition.
Design—Genital and systemic tenofovir concentrations in 34 women who acquired HIV (cases) 
were compared to 302 randomly selected women who remained HIV uninfected (controls) during 
the CAPRISA 004 trial. In total, 336 cervicovaginal fluid (CVF), 55 plasma, and 23 paired 
cervical and vaginal tissue samples were assayed by validated methods for tenofovir and tenofovir 
diphosphate (tenofovir-DP) detection.
Results—Tenofovir was detected in the genital tract in 8(23.5%) cases and 119(39.4%) controls 
(p=0.076). Among those with detectable genital tract tenofovir, the median CVF concentrations 
were 97% lower in cases compared to controls, 476ng/ml versus 13821ng/ml (p=0.107). A total of 
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14.7% (5/34) of cases and 32.8 % (99/302) of controls were found to have tenofovir CVF 
concentrations above 100ng/mL (Odds Ratio (OR): 0.35, p=0.037). At a higher threshold, 8.8 
%(3/34) of cases and 26.2 % (79/302) of controls were found to have tenofovir CVF 
concentrations above 1000ng/mL (OR: 0.27, p=0.036). Plasma tenofovir concentrations were 
<1ng/mL in all women and were less frequently detected in cases (0%) than controls (16.7 %) 
(p=0.031). Returned used tenofovir gel applicators and CVF concentrations were correlated 
(Spearman r=0.22, p=0.001).
Conclusion—A tenofovir concentration of ≥100ng/mL in CVF was associated with 65% (CI: 
6%; 87%) protection against HIV, while a ≥1000ng/mL concentration correlated with 76% (CI: 
8%; 92%) protection against HIV infection.
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Introduction
The global HIV epidemic is driven by sexual transmission with an estimated 2.1 million 
individuals acquiring HIV in 20131. Research efforts to prevent new infections focusing on 
drug targets, particularly antiretrovirals, are underway 2. Recent successful trials testing 
antiretrovirals for prevention have demonstrated the efficacy of oral tenofovir containing 
products in preventing HIV infection 3-5. In 2010, the Centre for the AIDS Program of 
Research in South Africa (CAPRISA) 004 trial assessed the safety and effectiveness of the 
1% vaginal gel formulation of tenofovir. This study found a 39% reduction in risk for 
acquisition of HIV 6 and a 51% reduction in HSV-2 infection 7. In 336 subjects in this study 
who were considered to be at least 80% adherent to tenofovir gel, the reduction in risk for 
HIV acquisition was 54%.
The concentration of tenofovir achieved in the vaginal tract in the CAPRISA 004 trial, 24 
hours after coitally dependent dosing, was estimated to be ≈105ng/mL 8. Two previous 
animal studies of tenofovir 1% gel in pig-tailed macaques and humanized bone marrow liver 
thymic (BLT) mice have demonstrated 88-100% efficacy against viral acquisition9,10. 
However, the limited data on drug exposure in these animals does not allow direct human 
exposure comparisons. Therefore, it is unclear whether the more modest clinical trial results 
were due to intermittent adherence, dissimilar drug exposure, or both. Differentiating 
between these two etiologies are difficult using the traditional adherence measures of self-
report or, as in the case of CAPRISA 004, returned used gel applicator counts, as none of 
these directly capture intervention-taking behavior.
Using a pharmacologic measure may allow better interpretation of adherence from samples 
stored during a clinical trial, and could eventually provide real-time information to guide 
behavioral interventions. Also, since standard Phase II drug development dose-ranging 
pharmacokinetic-pharmacodynamic studies used to generate clinical Emax models (non-
linear model using dose-response analysis) of efficacy are not straight-forward for HIV 
prevention, pharmacologic data from placebo-controlled clinical trials may provide some 
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insight into the exposure of tenofovir required in the female genital tract to protect against 
infection.
The purpose of this study was to assess the relationship between local/systemic tenofovir 
concentrations and HIV acquisition in order to identify a pharmacokinetic marker of 
adherence as a correlate of protection in women.
Patients and Methods
Patients and Study Design
The CAPRISA 004 trial was conducted between May 2007 and March 2010 in KwaZulu-
Natal, South Africa at the CAPRISA Vulindlela Clinical research site in Vulindlela, a rural 
community 150 km west of Durban (rural) and at the CAPRISA eThekwini Clinical research 
site in the Durban city centre (urban). The source population for this cohort has been 
described elsewhere 11.
Participant screening, enrolment and randomization procedures have been described in detail 
previously6. Briefly, volunteers were provided with study information in English and/or 
isiZulu and those agreeing to continue with study participation were eligible if they were 18 
to 40 years of age, willing to provide written informed consent for screening, agreed to 
provide adequate locator information for study retention purposes, agreed to adhere to study 
visit schedule, were sexually active (defined as having had vaginal intercourse at least twice 
within the last 30 days prior to screening), HIV negative, not pregnant, agreeable to be on a 
non-barrier form of contraception, creatinine clearance of >50 ml/min using the Cockcroft 
and Gault method 12 and no evidence deep epithelial disruption on pelvic examination. 
Volunteers were excluded if they had an untreated sexually transmitted infection. Within 30 
days of the first screening visit, returning eligible volunteers were randomly assigned to 
receive either 1% tenofovir gel or the hydroxyethylcellulose (HEC) placebo in a 1:1 ratio. 
Participants received an assigned study gel in quantities guided by the frequency of coital 
activity.
From May 2007 to January 2009, 2160 women were screened and 1085 were enrolled, of 
whom 889 were included in the primary analysis. Women followed a dosing strategy 
referred to a “BAT24”: insert one dose of gel within 12 hours before sex and a second dose 
of gel as soon as possible within 12 hours after sex and no more than two doses of gel in a 
24-hour period. Participants had monthly follow-up visits for 30 months. Participants were 
requested to return their used (from October 2007 onward) and unused applicators at every 
visit. Each month, the applicators returned by women as used and unused were counted, 
reconciled against the number dispensed, and thereafter discarded. At months 3, 12, 24 and 
at exit, blood plasma and cervicovaginal fluid aspirates were collected for pharmacokinetic 
analysis. Upon detection of HIV seroconversion, vaginal and cervical tissue biopsies were 
also obtained.
Sample Processing and Analyses
Tenofovir was quantified in blood plasma and cervicovaginal fluid (CVF). Tenofovir and 
tenofovir diphosphate was quantified in vaginal and cervical tissue. For each blood plasma 
Kashuba et al. Page 3













sample, 4mL of blood was collected in a tube containing K-EDTA. Within 30 minutes of 
collection, whole blood was centrifuged at 800g for 10min at 4°C. Plasma was pipetted into 
cryovials and stored at -80°C until analysis. Specialty collection syringes (UNC CFAR 
Vaginal Specimen Aspirators) were used to obtain directly-aspirated, undiluted CVF 
samples. After collection, samples were expelled into a cryovial and stored at -70°C until 
analysis. To prepare the mucosal tissue for biopsy, the areas of the planned biopsies were 
gently wiped with a small cotton swab moistened with warm saline followed by a small 
cotton swab with betadine. Topical gel containing lidocaine 25mg/prilocaine 25mg/g was 
applied to biopsy area for anesthesia. A medium-Tischler biopsy forceps was used to obtain 
one 5 × 3 mm biopsy from the vaginal wall and one 5 × 3 mm biopsy from the ectocervix. 
Each biopsy was placed in a pre-weighed individual vial and weighed, snap frozen in liquid 
nitrogen, and stored at -80°C until transport.
At the end of the study, samples were shipped on dry ice to the UNC Center for AIDS 
Research Clinical Pharmacology and Analytical Chemistry Laboratory at the University of 
North Carolina at Chapel Hill.
Sample Analysis
Analysis of all samples was performed using an LC-MS/MS method that quantified 
tenofovir and tenofovir diphosphate simultaneously, as described previously 13. For blood 
plasma, the calibration curve for tenofovir ranged from 0.25-200 ng/mL. Across 3 quality 
control concentrations, intra-day accuracy and precision was >99% and <12%, respectively, 
and inter-day accuracy and precision was >90% and <13%, respectively. For CVF, the 
calibration curve for tenofovir ranged from 2-1000 ng/mL. Intra-day accuracy and precision 
was >93% and <8%., and inter-day accuracy and precision was >97% and <5%. For vaginal 
and cervical tissue, a calibration curve with a range of 2-2,000 ng/mL for tenofovir, and 
10-10,000 ng/mL for tenofovir-DP was prepared. Intra-day accuracy and precision for 
tenofovir was >90% and <10%, respectively: for tenofovir-DP it was >94% and <9%, 
respectively. Inter-day accuracy and precision for tenofovir was >93% and <5%, 
respectively: for tenofovir-DP it was >98% and <6% respectively.
Statistical Analyses
The demographic characteristics at baseline were summarized using basic descriptive 
statistics. Fisher's exact test was used for the analysis of categorical data, and unpaired t-
tests or the Wilcoxon rank sum tests for the analysis of continuous data.
A nested case-control study, post-trial, was conducted in order to determine a correlate of 
protection related to drug concentration. For the cases, post-infection samples of the HIV 
seroconverters on the active arm were selected. Controls were selected randomly from those 
who did not acquire HIV. Only visits with tenofovir concentrations measured were 
considered. Detectable concentrations below the limit of quantification (BLQ) were imputed 
to be one-half of the lower limit of quantification (the lowest point on the standard curve) 
and values below the limit of detection (BLD) were set to 0 ng/mL. Tenofovir threshold 
concentration cut points were selected as follows: (1) Tenofovir = 0 ng/mL: indicates that 
tenofovir concentration was BLD (2) Tenofovir ≥ 1 ng/ml: indicates that any tenofovir was 
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present, (3) Tenofovir ≥ 100ng/ml: tenofovir concentration expected in plasma and 
cervicovaginal fluid following oral dosing and (4) Tenofovir ≥ 1000ng/ml: tenofovir at 
concentrations at or above the surrogate level of protection identified previously 8. Logistic 
regression was performed comparing the different tenofovir thresholds in cases and controls. 
An adjusted model was fitted controlling for possible confounders: age, site, marital status, 
education, condom at last sex act and time on study at sample collection.
Spearman correlation was used to assess the relationship between tenofovir plasma and CVF 
concentrations, as well as between tenofovir and tenofovir-DP concentrations within both 
vaginal and cervical tissue. Wilcoxon signed rank test was used to compare both tenofovir 
and tenofovir-DP concentrations between vaginal and cervical tissue. Spearman correlation 
was also used to compare CVF tenofovir concentrations to the number of returned used 
applicators brought back at monthly study visits. All analyses were performed using two-
sided tests. SAS software version 9.3 (SAS Institute Inc., Cary) was used for analysis while 
graphs were created using GraphPad Prism version 5.
Regulatory considerations
The protocol for the primary study, informed consent forms and study related materials were 
reviewed and approved by the University of KwaZulu-Natal Biomedical Research Ethics 
Committee, Ref: E111/06, the Protection of Human Subject Committee in the Office of 
International Research Ethics at FHI360 Ref: 9946, and the South African Medicines 
Control Council (MCC), Ref: 20060835. The trial was registered with ClinicalTrials.gov, 
number NCT 00441298.
Results
Tenofovir concentrations in cases and controls
Of the 889 women enrolled in CAPRISA 004, 445 were randomized to the tenofovir gel arm 
and of these, 340 had at least one tenofovir CVF concentration measured. Of the 340 women 
with tenofovir concentration data, post infection samples were available for 34 of the 38 
HIV seroconverters (cases). The remaining four seroconverters only had pre-infection 
samples available and were therefore excluded. Control samples were selected at a random 
visit from the remaining 302 women who remained HIV negative. No statistically 
significant differences in demographic characteristics were seen between HIV cases and 
controls (Table 1). Median age in both cases and controls were 23 years, with approximately 
60% of women representing the rural site. The 336 samples included in this case control 
analysis were obtained at a median of 9 days (IQR 3 – 27) after the last reported gel use 
(Figure 1).
Tenofovir was detected in the genital tract in 23.5% (8/34) cases and 39.4% (119/302) 
controls (p=0.076). Among those with detectable tenofovir in the genital tract, the median 
CVF concentrations were 97% lower in cases compared to controls, 476ng/ml versus 
13821ng/ml (p=0.107) (Figure 2). With 1000ng/mL as a correlate of protection, we found 
8.8% (3/34) of cases and 26.2% (79/302) of controls had tenofovir CVF concentrations 
above this threshold (OR: 0.27, p=0.036). After adjustment for multiple covariates, a 
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concentration of 1000ng/mL in the CVF was associated with 76% protection against HIV 
(adjusted p=0.024) (Table 2). At lower tenofovir concentrations, protection against HIV was 
concomitantly lower, with efficacy of 53% (p=0.076) and 65% (p=0.037) when tenofovir 
CVF concentrations were ≥1 ng/mL and ≥100ng/mL, respectively. For the latter tenofovir 
cut-off concentrations, the efficacy against HIV was 53% (adjusted p=0.089) and 67% 
(adjusted p=0.034, after adjusting for age, site, marital status, education, condom at last sex 
act and time on study at sample collection.
There was a correlation, though not very strong, between CVF tenofovir concentrations and 
number of returned used applicators (Spearman r=0.22; p<0.001) in women (331/336) with 
applicator data available.
Blood plasma samples
Plasma tenofovir concentrations were measured in 55 women randomized to tenofovir gel. 
Of these, 93% (51/55) were BLD or BLQ. In all subjects, plasma concentrations were less 
than 1ng/mL, but nonetheless were detected less frequently in cases than in controls. 
Tenofovir was detected in plasma in none (0/31) of the HIV positive women and in 16.7% 
(4/24) of the HIV negative women. Of the 55 plasma tenofovir concentrations, 54 had a 
tenofovir CVF concentration on the same collection date. Plasma and CVF tenofovir 
concentrations were moderately correlated with a Spearman correlation coefficient of 0.46 
(p=<0.001). In the four women with detectable tenofovir in plasma, their median tenofovir 
concentration in CVF was 312 482 ng/ml (IQR 121 298 – 510 512). The four women with 
detectable concentrations reported gel use at a median of 5 days prior to sampling (IQR 3 – 
18), while the remaining undetectable plasma concentrations were in visits where women 
reportedly used the gel at a median of 10 days ago (IQR 4 – 83) (p=0.313).
Cervical and vaginal biopsies in seroconverters
Cervical and vaginal biopsies were collected in 23 of 38 HIV seroconverters at a median of 
37 days post-infection (IQR 29 – 67) and a median of 43 (IQR 20-93) days after the last 
reported gel insertion. In total, 6 women had detectable tenofovir and 6 women had 
detectable tenofovir-DP from the 23 cervical and 23 vaginal biopsies collected. Tenofovir-
DP concentrations correlated with tenofovir concentrations in both vaginal and cervical 
tissue (rho=0.61, p=0.002 and rho=0.53, p=0.009, respectively). The median tenofovir 
concentration was 10ng/g (IQR 7.1-16.7) and 10ng/g (IQR 8.3-25.0) in cervical and vaginal 
tissue, respectively. Among those with detectable tenofovir- DP, median (IQR) Tenofovir-
DP concentrations in vaginal and cervical biopsies were 79 fmol/mg (IQR 0-186) and 0 
fmol/mg (IQR 0 – 93), respectively.
Discussion
Following topical application, the tenofovir concentration in the genital compartment 
provides a potential clinical correlate of protection against HIV infection, with 76% 
effectiveness demonstrated when genital concentrations are in excess of 1000ng/mL. In 
women with no detectable tenofovir in the genital tract, protection against HIV was not 
observed while the detection of any genital tenofovir (>1ng/mL) was associated with 53% 
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effectiveness. The increasing levels of effectiveness associated with log increases in 
tenofovir concentrations highlights the importance of adherence to attain high levels of 
protection against HIV. This is further supported by the recent outcome of the VOICE trial 
that failed to demonstrate the protective efficacy of tenofovir gel due to low adherence to the 
prescribed daily gel application schedule 14.
Tenofovir was seldom detected systemically in the CAPRISA 004 trial, confirming that 
intermittent topical application achieves limited and short-lived systemic tenofovir exposure. 
With intermittent topical application, there was no observed correlation between random 
systemic tenofovir concentrations and protection against HIV. Since the median serum 
tenofovir Cmax is 3.0 ng/mL at 2.1 hours after gel insertion and was <1ng/mL at 24 hours 
after insertion 15, a coital dosing strategy would not produce consistently detectable 
tenofovir systemically. Further, the lack of detectable tenofovir in blood plasma in this 
analysis supports the findings of limited drug-related systemic adverse effects 16 and may 
explain why no tenofovir resistance was observed in plasma viruses, even in women who 
continued applying tenofovir gel, for approximately 3 -4 weeks, after HIV infection in the 
CAPRISA 004 trial 6.
The assays on the vaginal and cervical tissue from the genital biopsies showed that 
concentrations of the active form of tenofovir, tenofovir-DP, correlated with concentrations 
of the tenofovir pro-drug, noting that the gel contains only the tenofovir pro-drug. Despite 
the biopsies being sampled a median of 43 days since last gel insertion, tissue concentrations 
were detected in 30.4 % of women sampled.
The specified concentration of genital tract tenofovir, or intracellular tenofovir-DP required 
to protect women from HIV infection is unknown. Protective concentrations modulated by 
additional acquisition risk factors such as genital inflammation and presence of sexually 
transmitted infection/s are yet to be described. Two animal studies have previously 
demonstrated >80% efficacy of tenofovir 1% gel. In 2009, 100% protection from 
SHIVSF162P3 acquisition was found in 6 pig-tailed macaques given 3mL of a tenofovir 1% 
vaginal gel 30min prior to viral challenge twice weekly for 10 weeks 9. In 2011, 88% 
protection from HIV-1JR-CSF acquisition was demonstrated in 8 humanized BLT mice given 
20μL of a tenofovir gel 4 hours prior to, and 4 hours after, a single viral challenge10.
In the macaque model, Dobard et al 17 analyzed tenofovir-DP concentrations in isolated 
vaginal lymphocytes at necropsy after dosing with 3mL of tenofovir 1% gel. The authors 
demonstrated high concentrations (median 1810, range 1312–2684 fmol/106 cells) 4h post-
dose, where tenofovir 1% gel is 100% efficacious in macaques. At 72h after a dose of 
tenofovir gel, when protective efficacy in macaques is 67%, Tenofovir-DP concentrations 
are 86% lower (252 (196-295) fmol/106 cells). These data can't be directly compared to 
women using tenofovir gel, as isolated vaginal lymphocytes cannot be obtained in sufficient 
quantities by standard biopsy techniques. However, they do demonstrate that a tissue 
concentration-effect relationship exists for tenofovir gel and should be defined in human 
tissue.
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In the CAPRISA 004 study, as expected, tenofovir CVF exposures were highly variable 0-3 
days post-dose. For those women who reported using the gel within 24h of their visit, CVF 
concentrations were ∼ 100,000 ng/mL. These concentrations are similar to a recent Phase I 
investigation of tenofovir 1% gel by Schwartz et al 18. However, one to 3 days post-dose, 
CVF concentrations in the women in the CAPRISA 004 study were up to 100-fold lower 
(∼1000ng/mL). This is not unexpected due to the phase I investigation being conducted 
under rigorous restricted conditions while the CAPRISA 004 study participants were 
exposed to sexual activity and accompanying practices. Yet this concentration of 1000 
ng/mL was useful in predicting efficacy in this case-control analysis. Based on the 
previously-established ∼10:1 relationship between CVF and vaginal tissue concentrations, 
and the 3% molar conversion rate between tenofovir and tenofovir-DP in vaginal tissue 18, 
we estimate the CVF concentration of 1000ng/mL should yield 500 fmol/mg of tissue of 
tenofovir-DP. Whether this concentration will be directly predictive of efficacy is yet to be 
determined.
These case-control dose-response data are consistent with preliminary analysis of the 
CAPRISA 004 CVF concentrations 8 and recently published data in PrEP trials testing oral 
tenofovir-containing products. In the Partners PrEP trial, 81% of blood samples had 
detectable tenofovir and HIV efficacy was 75% in that trial 3. Similarly, in the TDF2 19, 
iPREX 5 and FEM-PrEP 20 trials, 79%, 51% and 26% of blood samples had detectable 
tenofovir with a corresponding HIV protection point estimate of 62%, 44% and 6% 
respectively. Most recently, the MTN003 trial failed to show efficacy of oral TDF, oral 
Truvada, and topical Tenofovir 1% gel with tenofovir detected in only 28%, 29%, and 23% 
of blood samples, respectively.14
Finally, objective measures of adherence are critical to the interpretation of clinical trial 
data. Measurement of adherence in HIV prevention trials using self-reports or pill counts 
have been shown to overestimate adherence 21,22. Utilizing used applicator counts, the 
CAPRISA 004 investigators determined that tenofovir 1% gel could confer 52% protection 
against HIV acquisition in those who were >80% adherent. However in this analysis, 
cervicovaginal fluid concentrations taken at a single visit only weakly correlated with the 
number of gel applicators used the previous month. Self -reports of gel insertion compared 
to concentrations and model simulated data indicate that self-report of gel use are prone to 
bias. Based on a PK model developed for tenofovir gel dosing23, 62.5% of participants on 
active product could be considered adherent based on their tenofovir CVF concentrations 
(data not shown).
Limitations of this analysis include the inability to determine a threshold correlate of 
protection from tissue concentrations as genital tissue biopsies were not permitted in HIV 
uninfected women, furthermore tissue biopsies from seroconverters were performed on 
average more than 6 weeks after last gel insertion. It is also acknowledged that the time of 
last gel insertion was collected from participant self-report and is subject to recall bias. 
There was poor correlation between time of last dose and drug level in this trial. This was 
not unexpected as gel use was intermittent (coitally dependent), unscheduled, and not 
associated with clinic visits when PK samples were collected or seroconversion was 
detected.
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In conclusion, an analysis of tenofovir concentrations in the CAPRISA 004 trial 
demonstrated a potential correlation between genital tract concentrations of the drug and its 
effectiveness, with CVF concentrations >1000ng/mL being associated with 76% protection 
against HIV infection. Tenofovir 1% vaginal gel is still under clinical trial evaluation for 
safety and effectiveness in the current Follow-on African Consortium for Tenofovir Studies 
(FACTS) 001 trial, which is required for its registration for use as a topical PrEP agent. 
Based on this analysis, the attainment of this concentration during sexual exposure 
consistently may be necessary to achieve high levels of protection against HIV. Achieving 
high levels of gel adherence is therefore going to be essential for PrEP trials, without which, 
an efficacious product may be found spuriously to be ineffective. Importantly. maintaining 
high adherence in HIV prevention trials is critical in light of the urgent need for the 
prevention of sexually transmitted HIV in young women in Africa.
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Figure 1. Cervicovaginal Fluid Concentrations of Tenofovir versus reported days since last gel 
use in cases and controls
TFV=Tenofovir, BLD=below the limit of detection, BLQ=below the limit of quantitation
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Figure 2. Cervicovaginal tenofovir concentrations for HIV cases and controls
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Table 1








Median age (IQR) 23 (20 – 27) 23 (20 – 26) 23 (20 – 27) 0.478
Rural % (n) 66.4% (223) 64.7% (22) 66.6% (201) 0.849
Completed high school % (n) 40.2% (135) 32.4% (11) 41.1% (124) 0.361
Married % (n) 5.4% (18) 0.0% (0) 6.0% (18) 0.235
Stable partner % (n) 92.6% (311) 100% (34) 91.7% (277) 0.092
Casual partner % (n) 8.3% (28) 8.8% (3) 8.3% (25) 1.000
Lives with regular partner % (n) 13.0% (43) 8.8% (3) 13.5% (40) 0.595
Income per month (R=South African Rands)
 None or <R1000 91.4% (307) 88.2% (30) 91.7% (277) 0.597
 R1001-R5000 8.0% (27) 11.8% (4) 7.6% (23)
 >R5001 0.6% (2) 0.0% (0) 0.7% (2)
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